A phase 2, multicenter study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in patients with HCC at high risk of recurrence after curative resection

被引：0

作者：

Liang, Tingbo ^{[1
]}

Zhang, Zongli ^{[2
]}

Zheng, Jinfang ^{[3
]}

Wang, Yijun ^{[4
]}

Zhang, Jialin ^{[5
]}

Li, Bo ^{[6
]}

Ma, Tao ^{[1
]}

Xu, Yunfei ^{[2
]}

Wu, Changxiong ^{[3
]}

Sun, Quan ^{[4
]}

Meng, Yiman ^{[5
]}

Yang, Xiaoli ^{[6
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[2] Shandong Univ, Qilu Hosp, Jinan, Peoples R China

[3] Hainan Gen Hosp, Haikou, Hainan, Peoples R China

[4] Tianjin Third Cent Hosp, Tianjin, Peoples R China

[5] China Med Univ, Hosp 1, Shenyang, Peoples R China

[6] Southwest Med Univ, Affiliated Hosp, Luzhou, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT546

引用

页数：1